The therapy, haploidentical bone marrow transplant with thiotepa and posttransplant cyclophosphamide, is as safe and more affordable than the recently FDA-approved myeloablative gene therapy and gene editing treatments.

The Vanderbilt Stem Cell Transplant and Cellular Therapy Symposium offers clinicians detailed information on the latest developments for hematological diseases, ranging from immunotherapies for blood cancers to new, curative therapies for sickle cell disease.

Vanderbilt's Michael DeBaun, MD, MS, MPH, has been elected president-elect of the American Pediatric Society.

Nateqi's can-do attitude and dedication earn him a Credo Award.

Michael DeBaun, MD, MPH, has been awarded the American Society of Hematology’s 2019 ASH Mentor Award for his sustained and outstanding commitment to the training and career development of early career hematologists.

Two factors commonly used to evaluate patients with sickle cell disease are associated with each other and can predict increased mortality, Vanderbilt researchers have discovered.

Vanderbilt University Medical Center is part of a 6-year, $4.4 million grant from the National Institutes of Health to improve the use of prescribed medication by sickle cell patients.